

camurus®

Company presentation

February 2025



Forward looking statements

This presentation contains forward-looking statements that provide our expectations or forecasts of future events such as new product developments and regulatory approvals and financial performance.

Camurus is providing the following cautionary statement. Such forward-looking statements are subject to risks, uncertainties and inaccurate assumptions. This may cause actual results to differ materially from expectations and it may cause any or all of our forward-looking statements here or in other publications to be wrong. Factors that may affect future results include currency exchange rate fluctuations, delay or failure of development projects, loss or expiry of patents, production problems, unexpected contract, patent, breaches or terminations, government-mandated or market-driven price decreases, introduction of competing products, Camurus' ability to successfully market products, exposure to product liability claims and other lawsuits, changes in reimbursement rules and governmental laws and interpretation thereof, and unexpected cost increases.

Camurus undertakes no obligation to update forward-looking statements.

Camurus snapshot



Rapidly growing commercial stage company

Leader in opioid dependence treatment with Buvidal® and Brixadi® weekly and monthly depots



Advancing late-stage pipeline with blockbuster potential

Prospect for multiple new approvals in CNS and rare disease indications



Unique FluidCrystal® technology platform

Commercially validated with a broad range of applications



Strong operational and financial performance

Sustainable profitability since 2022



Listed on
Nasdaq Stockholm
Ticker **CAMX**;
Employees: **250+**



Strategy for continued value creation

- 1 Grow Buvidal/Brixadi sales and expand to new markets
- 2 Advance R&D pipeline to new approvals and launches
- 3 Diversify and grow through business development
- 4 Drive operational excellence and sustainable profitability

Camurus' vision 2027

Sustainable value creation for all stakeholders:

5x

Five-fold revenue growth (to SEK 4.5 billion)



Establishment of US commercial infrastructure

4

Approvals for four R&D pipeline programs

~50%

Operating margin around 50 percent

Exiting 2024 with positive momentum




- Leadership in long-acting treatment of opioid dependence
- Double-digit Buvidal sales growth in Europe, MENA and Australia
- Best-in-class launch of Brixadi® in the US
- Own US organization established for Oclaiz™ launch

- Positive final results from 52-week ACROINNOVA 2 study in acromegaly
- CAM2029 US NDA and EU MAA regulatory reviews advanced
- CRL resolution ongoing in the US
- SORENTO and POSITANO studies advancing in GEP-NET and PLD
- Clinical study initiated for once-monthly semaglutide, CAM2056

- Solid financial performance
- FY result exceeded earlier raised estimates
- Meaningful investment in R&D and US infrastructure
- Cash position strengthened to ~ SEK 2.9 billion
- New HQ and laboratories established


Strong financial development

Revenues



- One-time revenue related to Brixadi US approval
- Revenues excl. one-times for Brixadi US approval

Profit before tax



- One-time revenue related to Brixadi US approval
- Profit before tax excl. Brixadi US approval revenue

Full year 2025 guidance

Revenue


SEK 2.7 – 3.0 billion
+ 45 – 61% vs. 2024

Profit before tax


SEK 0.9 – 1.2 billion
+ 63 – 117% vs. 2024

FluidCrystal[®] extended-release technology

- ✓ Easy and convenient administration
- ✓ Rapid onset & long-acting release
- ✓ Controlled by composition, liquid crystal phase structure and biodegradation
- ✓ Applicable across substance classes
- ✓ Compatible with prefilled syringes, auto-injector pens, and other advanced devices
- ✓ Manufacturing by standard processes



Broad and diversified product portfolio and pipeline



Other clinical stage programs include CAM2032 (prostate cancer), CAM2043 (PAH³), and CAM2047 (CINV⁴)



Opioid
dependence

camurus®



Buvidal – game changing opioid dependence treatment

Weekly and monthly, subcutaneous buprenorphine for individualized treatment of opioid dependence within a framework of medical, social and psychological treatment in adults and adolescents 16 years or over¹

“Buvidal became my way out”

Justin, Buvidal patient in Australia

¹ SmPC Buvidal

Buvidal has demonstrated significant benefits to patients and society

- ✓ Superior treatment outcome and patient satisfaction¹⁻⁴
- ✓ Blocks subjective opioid effects from first dose²
- ✓ Reduces treatment burden and improve quality of life^{4,5}
- ✓ Decrease risk of diversion, misuse and pediatric exposure^{6,7}
- ✓ Provides cost savings⁸

¹Lofwall et al. *JAMA Int. Med.* 2018;178(6): 764-773; ²Walsh et al, *JAMA Psychiatry* 2017;74(9):894-902; ³Frost, M., et al. *Addiction.* 2019;114(8):1416-1426. doi: 10.1111/add.14636; ⁴Lintzeris, N., et al. *JAMA Network Open.* 2021;4(5):e219041. doi:10.1001/jamanetworkopen.2021.9041, ⁵Barnett et al *Drug and Alcohol Dependence* 2021; <https://doi.org/10.1016/j.drugalcdep.2021.108959>; ⁶EPAR for Buvidal; ⁷Dunlop, A. J., et al. *Addiction.* 2021. <https://doi.org/10.1111/add.15627>; ⁸Dunlop, A. Oral presentation at CPDD June 2020.



Towards global leadership in long-acting opioid dependence treatment

Wide and growing access to Buvidal and Brixadi

- Available across four continents
- More than 60,000 in treatment with Buvidal in Europe and Australia end-2024


Robust Buvidal sales growth

- 87% CAGR since first launch in 2019
- Target more than 100,000 patients on Buvidal in 2027

Market expansion continues

- Four market authorizations and several pricing and reimbursement applications under review

Strong growth of Buvidal sales



Accelerated growth of Brixadi in the US

US opioid crisis continues


- Overall, 6-7 million people with OUD in the US ¹⁻³
- Total number of ~2.3 million patients in treatment in 2023 of which ~1.8 million on buprenorphine⁴

Continued strong growth of Brixadi

- High QoQ growth (43% in Q4 2025)
- A majority of new patients transferring from sublingual buprenorphine products¹
- Other patients coming from LAI product or being direct initiations¹
- Brixadi LAIB est. share in the US approaching ~25%

Brixadi peak market potential est. > USD 1 bn⁶

Brixadi royalty by quarter



Buvidal/Brixadi – well differentiated

Convenient and flexible administration

- Weekly and monthly dosing
- Multiple dose strengths (four weekly, three monthly)
- Choice of multiple injection sites
- Thin needle and small dose volumes
- Room temperature stability (no cold chain required)

Strong scientific evidence base

- Superior efficacy and patient reported treatment satisfaction vs daily standard of care

Competitive label¹

- Switch from daily sublingual buprenorphine using conversion table for dose equivalency
- Direct initiation of treatment following a single dose of transmucosal buprenorphine

LAI features²

	<small>ONCE-MONTHLY</small> Sublocade™	Vivitrol®	<small>Weekly/Monthly</small> Buvidal® Brixadi®
Weekly dosing	–	–	✓
Monthly dosing	✓	✓	✓
Multiple doses	–	–	✓
Choice of inj. sites	–	–	✓
Smallest needle	(19G)	(20G)	✓ (23G)
Lowest dose volume	0.5–1.5mL	3.4mL	✓ 0.16–0.64mL
Room temp. storage	–	–	✓
Day one initiation	–	–	✓
Clin. data vs active control	–	–	✓
Launched	US, CAN, DE, AUS, SE, FI, IL	US	US, EU, UK, AUS

LAI – long acting injectable

¹Brixadi US label; ²See product information

Growing scientific evidence base

Strong scientific support for Buvidal/Brixadi

- Documenting effectiveness in different treatment settings
- Positive health economical outcomes
- More than 220 scientific publications
- Ongoing clinical studies exploring new applications

Selected planned scientific conference participation in 2025

	Q1/Q2 2025			Q3/Q4 2025				
International	ASAM 24-27 Apr Denver, US	ISAM 26-28 May Hamburg, DE	ALBATROS 10-12 Jun Paris, FR	CPDD 14-18 Jun New Orleans, US	IMiA 29-31 Aug Sydney, AUS	ATHS 21-24 Oct Biarritz, FR		
National (selected)	RCGP & AP 16 - 17 January Manchester, UK	APSEP 27-28 March Paris, FR	Addiction Z April - May Gold Coast, AUS	Fed. Addiction 22-23 May Angers, FR	Suchtmedizin 3 - 5 July Munich, DE	Suchtsymp. Oct Grundlsee, AT	APSAD 9-12 Nov Sydney, AUS	
	APP Feb Gold Coast, AUS	Sigtunadagarna Apr SE	Subst. Forum. May Mondsee, AT	SEPD 4-7 Jun Madrid, ES	Prison Congr. Oct Montpellier, FR	RCPsych Addict Oct London, UK	Addiktum Nov/Dec Helsinki, Fi	

Recent key publications¹⁻³

JOURNAL OF
Addiction Medicine
The Official Journal of the American Society of Addiction Medicine

ORIGINAL RESEARCH

Exploring Opioid Use Disorder Outcomes by Quantitative Urinalysis: Post Hoc Analysis of a Phase 3 Randomized Clinical Trial

Peterson, Stefan PhD; Nunes, Edward V. MD; Lofwall, Michelle R. MD; Walsh, Sharon L. PhD; Tiberg, Fredrik PhD

ORIGINAL RESEARCH

A Naturalistic Study of Individuals Involved in the Justice System Who Experienced Both Formulations of Extended-release Buprenorphine

Thomas R. Blue, PhD, Michael S. Gordon, DPA, Frank J. Vocci, PhD, Marc J. Fishman, MD, Shannon Gwin Mitchell, PhD, and Kevin Wenzel, PhD

ORIGINAL

Healthcare professionals' perception of prolonged-release buprenorphine in opioid use disorder. FOLIPRO Study

Percepción de los profesionales sanitarios sobre la buprenorfina de liberación prolongada en el trastorno por consumo de opioides. Estudio FOLIPRO

Rodrigo Orúa¹; Diego Sucunza Guibert²; María Yébenes Cortés³; Miguel Ángel Casado Gómez⁴; José Joaquín Antón Baganta⁵; Francisco Pascual Pastor⁶; Carlos Roncero⁷.

Octreotide SC depot, CAM2029

CAM2029 is a long-acting octreotide in development for three serious rare disease indications

- ✓ Acromegaly
- ✓ Gastroenteropancreatic neuroendocrine tumors (GEP-NET)
- ✓ Polycystic liver disease (PLD)

Designed for enhanced efficacy and patient convenience vs. current somatostatin receptor ligands (SRLs)

CAM2029 designed to address key limitations of current first-generation SRLs


- ✓ Ready-to-use FluidCrystal® technology
- ✓ Rapid onset and long-acting octreotide release¹
- ✓ 5-fold octreotide bioavailability vs Sandostatin LAR with potential for improved efficacy¹⁻³
- ✓ State-of-the-art, pre-filled autoinjector pen enabling convenient patient self-administration
- ✓ Subcutaneous administration with thin needle (22-gauge, 12.5mm)
- ✓ Room temperature storage




CAM2029 provides high SRL exposure

~5x higher octreotide plasma exposure for CAM2029 vs. Sandostatin LAR

– CAM2029 octreotide plasma levels in the range of immediate release octreotide



CAM2029 clinical program overview





Towards a patient-centric acromegaly treatment

Acromegaly is a rare, slowly progressive, chronic and serious condition typically caused by a tumor of the pituitary gland and overproduction of growth hormone. This results in excess growth of bones and tissue and a range of other symptoms and, if untreated, to premature death.




Positive results from ACROINNOVA 1 – CAM2029 provided robust biochemical control

ACROINNOVA 1 study design

- 24-week, randomized, double blind, placebo-controlled Phase 3 study

Patient population


- Biochemically controlled on first-generation SRL*



Superiority achieved

- 77.2% vs. 37.5% patients with IGF-1 \leq 1 ULN with CAM2029 versus placebo, $p=0,00018$

IGF-1 levels well controlled



CAM2029 improved

- Treatment convenience
- Acromegaly quality of life
- Patient satisfaction

CAM2029 was well tolerated

- Safety profile comparable to well established profile for first generation SRLs
- Most AEs were mild or moderate and transient injection site reactions and gastrointestinal side-effects
- No serious reactions related to CAM2029


Positive topline results from ACROINNOVA 2

ACROINNOVA 2 study design


- 52-week, open-label safety study with further extension

Patient population

- New patients; uncontrolled or controlled with IGF-1 < 2xULN
- Patients who completed ACROINNOVA 1



Improved acromegaly symptoms with CAM2029



ACROINNOVA 2 results

- Reinforcing long-term safety and effectiveness in ACROINNOVA 1
- Increased response rate from SoC baseline in new recruited patients
- Roll-over placebo patients from ACROINNOVA 1 regained IGF-1 control with CAM2029

Improved patient reported outcomes for CAM2029 vs standard-of-care baseline

- Treatment satisfaction
- Quality of life
- Injection experience



Potential to become new standard of care for GEP-NET

Neuroendocrine tumors are cancerous tumors originating from cells in the endocrine and nervous system. The tumors can occur throughout the body, most common they occur in the gastrointestinal tract and lungs. The disease can be chronic with serious symptoms and complications.




SORENTO assessing CAM2029 superiority in PFS vs SoC in patients with GEP-NET

Randomized, active-controlled Phase 3 study

- Randomized, multi-center, open-label, active-controlled Phase 3 study of CAM2029 vs. long-acting octreotide or lanreotide in patients with GEP-NET
- Single trial fulfilling regulatory requirements for safety and efficacy

Patient population

- Patients with confirmed, advanced and well-differentiated GEP-NET (grade 1 to grade 3)



Primary endpoint


- Superiority in progression free survival, PFS, vs. standard of care (first-line medical treatment)
- Assessed after 194 documented PFS events


Secondary endpoints include

- Overall survival
- PROs (e.g., treatment satisfaction, quality of life)
- Safety

Recruitment completed Dec 2023

- Enrollment of 332 patients across 12 countries exceeding randomization target (302)





Addressing unmet medical needs in polycystic liver disease

Polycystic liver disease is a rare, genetic, and chronic disorder characterized by progressive growth of cysts in the liver, which can cause severe symptoms and result in impaired quality of life for patients.





Clinical Phase 2/3 study in PLD fully recruited

POSITANO trial to assess efficacy and safety of CAM2029

- 53-week randomized, placebo-controlled, three-arm study
 - Randomization of 71 patients completed in Q1 2024
 - Primary endpoint is liver volume change
 - Key secondary endpoint is Camurus’ developed PRO, PLD-S
 - Multiple secondary endpoints, incl. quality of life, safety, etc.
- Open label extension extended to 120 weeks
 - Offer continued treatment in patients with expected benefits

Large unmet medical need in PLD

- Severe quality-of-life implications for patients with symptomatic PLD
- No labelled option available



CAM2029 progressing towards market with expected milestones 2025

AcroInnova™

Pivotal randomized placebo controlled and long-term safety trials in acromegaly

- ✓ Positive results from ACROINNOVA 1 and 2
- ✓ NDA acceptance in the US – CRL for manufacturer
- ✓ MAA validation in EU
- **NDA resubmission est. H1 2025**
- **MAA CHMP opinion est. mid 2025**

SORENTO™

Subcutaneous Octreotide Randomized Efficacy in Neuroendocrine Tumors

- ✓ SORENTO Phase 3 start Q4 2021
- ✓ SORENTO fully enrolled Q4 2023
- **Target number of events for primary endpoint est. late 2025 or early 2026**

positano™

Polycystic liver Safety and efficacy Trial with subcutaneous Octreotide

- ✓ POSITANO fully enrolled Q1 2024
- ✓ Orphan drug designation in EU and US
- **Clinical study results Q2 2025**

Medical information and dissemination of ACROINNOVA results

Medical affairs activities

- Presentation of ACROINNOVA results at scientific meetings and conferences
- MSL teams meeting with acromegaly stakeholders
- National and regional advisory board meetings

Planned scientific conferences in 2025

Q1 2025	Q2 2025	Q3 2025	Q4 2025		
ENETS  5-7 Mar Krakow PL	EASL  7-10 May Amsterdam NL	AACE  15-17 May Orlando US	IPS  9-11 Jul San Francisco US	NANETS  23-25 Oct Austin US	AASLD  7-11 Nov Washington US
DGE  19-21 Mar Baden-Baden DE	ESPE/ECE 10-13 May Copenhagen DK	ICE  26-27 June London UK	ENDO  12-15 Jul San Francisco US	ESMO  17-21 Oct Berlin DE	ENEA 3-5 Dec Marseille FR

ACRO


NET

PLD

ACROINNOVA 1 data recently published¹



Octreotide Subcutaneous Depot for Acromegaly: A Randomized, Double-blind, Placebo-controlled Phase 3 Trial, ACROINNOVA 1

Diego Ferone, Pamela Freda, Laurence Katznelson, Federico Gatto, Pinar Kadioğlu, Pietro Maffei, Jochen Seufert, Julie M Silverstein, Joanna L Spencer-Segal, Elena Isaeva, Alexander Dreval, Maria Harrie, Agneta Svedberg, Fredrik Tiberg 

¹ Ferone et al. *J. Clin Endocrinology & Metabolism* 2024

Commercial readiness for launch of CAM2029 (Oclaiz™) in acromegaly

Pre-launch activities in US and EU

- In-depth market research
- Optimizing the distribution and supply chain model
- Payor interactions and advisory meetings
- Increasing awareness of Camurus among stakeholders

CAM2029 peak sales estimates >2 billion USD across indications¹⁻⁴

	TERRITORY	PATIENT POPULATION	EST. PEAK PATIENT SHARE	EST. PEAK SALES
ACRO ¹	EU/AUS	16,500 ⁴	20 – 35%	€30 – 65 million
	US	10,000	25 – 40%	\$150 – 280 million
NET ¹	EU/AUS	68,000 ⁴	30%	€300 – 400 million
	US	37,000	40%	\$1,200 – 1,500 million
PLD ¹	EU/AUS	15-18,000 ⁴	30 – 40%	€80 – 100 million
	US	12-13,000	30 – 40%	\$200 – 300 million

¹Globe Life Science Aug 2022, data on file;

²Globe Life Science 2020, data on file

³Assuming €10-12.5ks (EU/AUS) and \$60-70K (US) per year net pricing in acromegaly, €15-20k (EU/AUS) and \$80-100K (US) per year net pricing in NET, and €17.5k (EU/AUS) and \$60K (US) per year net pricing in PLD

⁴Patient numbers extrapolated from 5EU estimates by assuming same prevalence across European countries and Australia



New early-stage programs

Several early-stage programs advancing

- ✓ CAM2056 recently entered clinical development
- ✓ Positive data and assessments of multiple preclinical drug candidates, including long-acting incretins




CAM2056 entered clinical development

CAM2056 – once monthly FluidCrystal semaglutide

- ✓ Completed preclinical program met target profile for pharmacokinetics, pharmacodynamics (incl. weight management) and tolerability


Clinical Phase 1 study initiated

- ✓ Phase 1 study initiated assessing pharmacokinetics, pharmacodynamics (incl. weight loss), tolerability and safety of CAM2056 in overweight or obese participants who are otherwise healthy
- Top-line results expected H2 2025



Potential indications

- Type 2 diabetes
- Weight management
- Inflammation
- Neuropsychiatric disorders
- Substance use disorders





Camurus expanding

New headquarter in Science Village, Lund

- ~3,700m² on the top floors of the “The Loop”
- Offices and state-of-the-art laboratories
- Capacity to grow ~250 people
- Sustainability profile with LEED Gold certification

US office ready to open

- Carnegie Center, Princeton, New Jersey

Camurus AB | Rydbergs torg 4, SE-224 84 Lund, Sweden
P +46 46 286 57 30 | info@camurus.com | camurus.com

Solid 2024 performance lays foundation for 2025 expansion

- Increasing Buvidal penetration in Europe and RoW
- Accelerating sales of Brixadi in the US
- Market approvals of CAM2029 in acromegaly
- Clinical results for CAM2029 and CAM2056
- Diversification through business development
- Positive financial outlook with expected high growth revenues (+45-61%) and profitability (+63-117%)



camurus®

Camurus AB | Rydbergs torg 4, SE-224 84 Lund, Sweden
P +46 46 286 57 30 | info@camurus.com | [camurus.com](https://www.camurus.com)



Shareholders and analyst coverage

Shareholders as of 31 January 2025	Number of shares	% of capital	% of votes
Sandberg Development AB	20,530,692	34.9	35.0
Fjärde AP-fonden	2,808,776	4.8	4.8
State Street Bank and Trust	2,348,571	4.0	4.0
Swedbank Robur Fonder	2,340,305	4.0	4.0
JP Morgan Chase Bank	2,332,383	4.0	4.0
Fredrik Tiberg, CEO	1,615,000	2.7	2.8
Handelsbankens fonder	1,308,393	2.2	2.2
Avanza Pension	1,201,710	2.0	2.1
The Bank of New York Mellon	881,778	1.5	1.5
Afa Försäkring	775,653	1.3	1.3
Norges bank	704,848	1.2	1.2
JP Morgan SE	641,227	1.1	1.1
SEB Investment Management	637,754	1.1	1.1
UBS	630,039	1.1	1.1
Camurus Lipid Research Foundation	480,150	0.8	0.8
Other shareholders	19,641,739	33.4	33.1
In total	58,879,018	100.0	100.0

Analysts

Carnegie
Erik Hultgård

DNB
Patrik Ling

Handelsbanken
Mattias Häggblom

Jefferies
Brian Balchin

Nordea
Viktor Sundberg

Pareto
Dan Akschuti

Bryan Garnier
Oscar Haffen Lamm

SEB
Christopher Uhde

Experienced and committed management team



Fredrik Tiberg, PhD
President & CEO, CSO
In Company since 2002
Holdings: 1,615,000 shares, 42,000 employee options and 4,000 PSP units

Education: M.Sc. in Chem. Eng., Lund Institute of Technology, PhD and Assoc. Prof. Physical Chemistry, Lund University.
Previous experience: More than 20 years executive leadership experience from the pharmaceutical industry. Prof Physical Chemistry, Lund University; Visiting Prof at Oxford University; Section Head, Inst. for Surface Chemistry.



Jon Garay Alonso
Chief Financial Officer
In Company since: 2022
Holdings: 1,450 shares, 24,000 employee options and 2,300 PSP units

Education: Bachelor in Business Administration by Universidad Comercial de Deusto. Executive MBA by IESE Business School.
Previous experience: More than 20 years experience from Finance within pharmaceutical and medtech companies, incl. Baxter, Gambro, Convatec, Bristol Myers Squibb.



Richard Jameson
Chief Commercial Officer
In Company since: 2016
Holdings: 29,193 shares, 24,000 employee options and 2,300 PSP units

Education: B.Sc. in Applied Biological Sciences from University West of England
Previous experience: General Manager, UK & Nordics for Reckitt Benckiser (2010 – 2013) and Area Director Europe, Middle East and Africa for Indivior (2013 – 2016).



Fredrik Joabsson, PhD
Chief Business Dev. Officer
In Company since 2001
Holdings: 40,170 shares, 16,000 employee options and 1,500 PSP units

Education: M.Sc. in Chemistry, PhD in Physical Chemistry, Lund University
Previous experience: More than 20 years of experience in pharmaceutical R&D, business development, alliance management and investor relations.



Markus Johansson
Senior VP R&D
In Company since: 2003-2017, 2019-
Holdings: 21,000 shares, 9,500 employee options and 1,500 PSP units

Education: Ph.D. in physical chemistry and M.Sc. in chemistry from Uppsala University.
Previous experience: More than 20 years of experience from pharmaceutical development and project management



Maria Lundqvist
Head of Global HR
In Company since 2021
Holdings: 16,000 employee options and 1,500 PSP units

Education: B.Sc. in Business and Economics, Uppsala University.
Previous experience: More than 20 years of experience of leadership roles within Human Resources, including HR Director Nordics at Teva Pharmaceuticals and HR positions at Tetra Pak, Vestas and AstraZeneca.



Torsten Malmström, PhD
Chief Technical Officer
In Company since 2013
Holdings: 35,363 shares, 16,000 employee options and 1,500 PSP units

Education: M.Sc. in Chemistry, PhD in Inorganic Chemistry, Lund University
Previous experience: More than 20 years of experience from pharmaceutical R&D including Director Pharmaceutical Development at Zealand Pharma, Director of Development at Polypeptide, Team Manager at AstraZeneca.



Annette Mattsson
VP Regulatory Affairs
In Company since: 2017
Holdings: 2,004 shares, 16,000 employee options and 1,500 PSP units

Education: Bachelor of Pharmacy, Uppsala University and Business Economics, Lund University
Previous experience: More than 25 years of experience within regulatory affairs, including European RA Director/Global RA Lead at AstraZeneca and Global RA Lead at LEO Pharma.



Alberto M. Pedroncelli
Chief Medical Officer
In Company since 2023
Holdings: 1,000 shares, 20,000 employee options and 1,500 PSP units

Education: MD University of Milan. Ph. D. endocrinology post-graduate school University of London
Previous experience: Head of Clinical Development and Medical Affairs Recordati, Senior Leadership positions Novartis, clinician and research fellow Dept. Endocrinology, University Hospital Bergamo, Italy



Behshad Sheldon
President Camurus Inc.
In Company since 2024
Holdings: 1,000 shares, 2,000 employee options and 1,500 PSP units

Education: B.Sc. in Neuroscience from University of Rochester
Previous experience: More than 25 years of experience from the international pharma industry, including President & CEO of Braeburn Pharmaceuticals and senior positions within Smithkline Beecham, Bristol-Myers Squibb and Otsuka Pharmaceuticals.



Agneta Svedberg
VP Clinical Dev.
In Company since: 2015
Holdings: 22,987 shares, 16,000 employee options and 1,500 PSP units

Education: M.Sc. In Radiophysics and B.Sc. In Medicine from Lund University, Executive MBA from Executive Foundation Lund
Previous experience: More than 25 years of experience in drug development, incl. as COO at Zealand Pharma, CEO of Cantargia, Senior VP Clinical Development at Genmab.



Bo A. C. Tarras-Wahlberg
VP Legal & Group General Counsel
In Company since 2024
Holdings: 1,500 PSP units

Education: LLM from Lund University and studies at Queen Mary College
Previous experience: More than 20 years of experience as lawyer and from international senior legal positions, incl. as Assoc. General Counsel at Baxter, Gambro, legal private practice and as law clerk at District Court.